Study guide
13.3 Exercise and Pharmacologic Stress Testing
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
13.3 Exercise and Pharmacologic Stress Testing
Key Takeaways Explain This Topic AI
NM technologists must recognize basic ECG waveforms, ischemia (ST depression/elevation), and serious arrhythmias that require stopping stress and getting help
Standard 12-lead placement (limb + V1–V6) and clean skin contact are required for diagnostic stress ECG monitoring
Bruce and modified Bruce treadmill protocols step speed/grade; bicycle ergometry is an alternative when treadmill is unsuitable
Know absolute/relative contraindications and termination criteria (drop in SBP, serious arrhythmia, severe angina, patient request, target endpoints)
Pharmacologic agents: adenosine, dipyridamole, regadenoson (vasodilators—caffeine hold; asthma/COPD cautions) and dobutamine (inotrope/chronotrope); know infusion/bolus timing, RP injection windows, side effects, and aminophylline reversal for vasodilators
Last updated: August 2026
13.3 Exercise and Pharmacologic Stress Testing
Quick Answer: Exercise (Bruce / modified Bruce / bike) is preferred when the patient can walk and the ECG is interpretable. Vasodilators (adenosine, dipyridamole, regadenoson) create coronary hyperemia when exercise is inadequate; dobutamine raises demand when vasodilators are contraindicated. Know leads , stop criteria , RP injection timing , side effects , and aminophylline reversal. Caffeine ruins vasodilator stress.
Stress testing is a team process. CNMT items still expect you to set up , monitor , inject on time , and recognize danger .
Basic ECG for the Nuclear Technologist
Conduction path: SA node → atria ( P ) → AV node/His–Purkinje → ventricles ( QRS ) → repolarization ( T ). Watch PR (AV conduction), QRS width (bundle branch/ventricular beats), and ST segment (ischemia zone during stress).
- Finding Concern Typical action
- ≥1 mm horizontal/downsloping ST depression Demand ischemia pattern Notify supervisor; may meet stop criteria
- ST elevation (non-Q leads) Severe ischemia/injury Stop ; urgent evaluation
- VT, VF, complete heart block, symptomatic bradycardia Life-threatening Stop ; emergency/ACLS response
- Unstable rapid AF / SVT with hypotension Unstable arrhythmia Stop ; treat per protocol
- Frequent polymorphic PVCs / R-on-T Malignant potential Alert; often terminate
You are not the final ECG reader, but you must not ignore alarms, severe pain with ST change, or collapse.
Lead Placement
Standard 12-lead monitoring:
- Leads Placement teaching
- Limb leads RA, LA, RL, LL (torso-modified/Mason–Likar positions common on treadmill)
- V1 4th ICS right sternal border
- V2 4th ICS left sternal border
- V3 Midway V2–V4
- V4 5th ICS midclavicular line
- V5 Level with V4, anterior axillary line
- V6 Level with V4–5, midaxillary line
Prep skin (shave/abrade as needed); fix loose electrodes—motion noise mimics arrhythmia. Baseline LBBB, paced rhythm, digoxin effect, or LVH with strain limits ECG ischemia diagnosis (favor imaging endpoints).
Exercise Protocols
Bruce treadmill: 3-minute stages increasing speed and grade (classically starts 1.7 mph / 10%). Goal often ≥85% maximum predicted HR (rough rule 220 − age ) unless symptoms force earlier stop. Inject MPI tracer at peak and continue exercise ~1 minute when safe.
Modified Bruce: gentler early stages for deconditioned or limited patients before standard workloads.
Bicycle ergometry: watt-stepped upright or supine bike when gait is limited or bike imaging geometry is preferred. Same HR, BP, and symptom rules apply.
Contraindications and Termination
Absolute contraindications (teaching—follow lab policy): acute MI (early), high-risk unstable angina, uncontrolled symptomatic arrhythmia, severe symptomatic AS, decompensated HF, acute PE/dissection/myocarditis-pericarditis, inability to cooperate safely.
Relative: left main disease, moderate stenotic valve disease, severe rest HTN, electrolyte extremes, HOCM with obstruction, high-grade AV block— clinician call .
Stop when… Examples
Absolute Sustained VT; severe angina with ST elevation; drop in SBP >10 mmHg with ischemia signs; cyanosis; near-syncope; cannot monitor
- Relative Progressive chest pain, marked ST depression, marked HTN, fatigue/cramp, patient request
- Goal reached Target HR/workload without ischemia—complete tracer dwell per protocol
Patient request to stop is honored for safety; convert to pharmacologic imaging if the study must finish.
Always record baseline BP/HR, stage-by-stage values, peak rate-pressure product when used, total exercise time, reason for stopping, and exact tracer injection clock time relative to peak stress or drug administration.
Pharmacologic Stress
Use when exercise is inadequate, when LBBB/paced rhythm makes exercise MPI artifact-prone (prefer vasodilator), or when ordered.
Vasodilators
Agent Delivery / duration RP injection timing Side effects Reversal
Adenosine IV ~ 140 µg/kg/min for ~4–6 min During infusion (often ~3 min into 6-min protocol) Flushing, chest pressure, dyspnea, AV block, ↓BP Stop infusion; aminophylline if needed
Dipyridamole IV ~ 0.56 mg/kg over ~4 min Tracer ~ 3–5 min after infusion (lab-specific) Same class; longer lasting Aminophylline
Regadenoson Fixed 0.4 mg IV bolus + flush Tracer ~10–20 s after flush Dyspnea, headache, flushing Aminophylline if needed
Vasodilator cautions: active wheezing / severe asthma or bronchospasm, high-grade AV block without pacemaker, profound hypotension, recent dipyridamole, and caffeine/theophylline not held . Uncontrolled bronchospasm is a hard stop; milder reactive-airway history may steer agent choice toward regadenoson under clinician judgment.
Dobutamine
Dobutamine (β-agonist) raises HR and contractility when vasodilators are contraindicated and exercise is impossible.
- Item Teaching values
- Infusion Escalate (e.g., 5→10→20→30→40 µg/kg/min q3 min—lab protocol)
- Adjunct Atropine if HR target unmet
- RP injection At peak HR / peak dose stage
- Side effects Palpitations, BP swings, arrhythmia, chest pain
- Control Stop infusion; β-blocker per clinician— not aminophylline
- Putting Timing Together with MPI
Confirm prep (caffeine, meds, consent, IV).
Choose exercise vs pharmacologic from order and safety screen.
Monitor ECG + BP + symptoms continuously.
Inject tracer at protocol peak (exercise peak, mid-adenosine, post-regadenoson, post-dipyridamole window, or peak dobutamine).
Recover; reverse drugs if needed; image after the correct delay .
Bottom line: protect the patient first, hit the physiology window second, and document anything that turns a defect into failed stress rather than true ischemia .